AstraZeneca has entered into a licensing agreement with Sino Biopharm for the development and commercialization of a respiratory drug, for which AstraZeneca will pay up to $1.9 billion. This deal grants AstraZeneca the rights to the drug outside of mainland China, with Sino Biopharm retaining rights within its home market. The $1.9 billion figure includes an upfront payment and potential milestone payments tied to development and sales achievements.
This agreement highlights AstraZeneca's continued focus on expanding its respiratory franchise. The company aims to strengthen its portfolio of treatments for conditions like asthma and chronic obstructive pulmonary disease (COPD) through strategic partnerships and acquisitions. Previously, AstraZeneca has made moves to bolster its respiratory offerings, including acquiring Almirall's respiratory franchise for an initial $875 million with potential for up to $1.22 billion in milestones in 2014, and rights to Actavis' branded respiratory portfolio in the US and Canada in 2015.
The collaboration with Sino Biopharm also underscores AstraZeneca's ongoing efforts to engage with Chinese pharmaceutical companies. Earlier, in June 2025, AstraZeneca signed an AI-led research deal with China's CSPC Pharmaceutical Group worth up to $5.3 billion for chronic diseases, including an upfront fee of $110 million and potential milestone payments of up to $1.62 billion, plus sales-related milestones of $3.6 billion. These partnerships are part of AstraZeneca's strategy to revive and strengthen its business in China, which is its second-biggest market. Sino Biopharm itself collaborates with global partners, as evidenced by its participation in the 8th China International Import Expo in November, where it partnered with AstraZeneca (China) and MediTrust Health on neoplasm treatment and its core enterprise, Chia Tai Tianqing, signed a strategic cooperation framework agreement with AstraZeneca (China) for lung cancer combination therapy research. The current deal aims to leverage the research and development strengths of both companies for potential global market development.
